Wellington Biomedical Innovation Master Investors (Cayman) I L.P. - 27 Mar 2024 Form 3 Insider Report for Boundless Bio, Inc. (BOLD)

Role: 10%+ Owner
Signature: Wellington Biomedical Innovation Master Investors (Cayman) II L.P. By: Wellington Management Company LLP, as Investment Adviser /s/ Peter McIsaac, Title: Authorized Person
Issuer symbol: BOLD
Transactions as of: 27 Mar 2024
Net transactions value: $0
Form type: 3
Filing time: 27 Mar 2024, 21:07:37 UTC
Previous filing: 21 Nov 2022
Next filing: 02 Apr 2024
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	BOLD	Series B Preferred Stock							27 Mar 2024	Common Stock	189,933		Direct	F1
holding	BOLD	Series C Preferred Stock							27 Mar 2024	Common Stock	366,300		Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of Series B Preferred Stock is convertible into shares of Common Stock, on a 19.5-for-1 basis, into the number of shares of Common Stock shown in column 3 without payment of further consideration at any time at the holder's election and will convert immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.
F2	Each share of Series C Preferred Stock is convertible into shares of Common Stock, on a 19.5-for-1 basis, into the number of shares of Common Stock shown in column 3 without payment of further consideration at any time at the holder's election and will convert immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.